Endpoints
tumour, TTP
TTP, TUMOUR
The primary endpoint was the clinical activity of O + D, as measured by progression-free survival at 6 months (PFS6). PFS6 is the Kaplan–Meier estimate of the proportion of patients who remain alive and progression-free at 6 months from the date of registration. Secondary endpoints included objective tumour response, overall survival (OS), ratio of time to progression (TTP) on trial (TTP2), to TTP on the last line of therapy (TTP1) prior to trial entry, health-related quality of life measured by the EORTC QLQ-C30 [